The short version of visceral adipose tissue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-12 and is reviewed periodically as new material appears.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
=== United States === The approach in the United States to stop money laundering is usually broken into two areas: preventive (regulatory) measures, and prosecutorial measures. In the United States, whistleblowers can report money laundering activities to the Financial Crimes Enforcement Network (FinCEN) or the Securities and Exchange Commission (SEC) if the case also implicates a security.
Phenylhydrazine reacts with reducing sugars to form hydrazones known as osazones, which was developed by German chemist Emil Fischer as a test to differentiate monosaccharides. Hydrazones having 1,3-diketomoiety are also known in literature. More generally, diazonium ions react with carbon acids in the Japp-Klingemann reaction to give hydrazones via tautomeric rearrangement of a diazo intermediate.
coding strand Also sense strand, positive (+) sense strand, and nontemplate strand. The strand of a double-stranded DNA molecule whose nucleotide sequence corresponds directly to that of the RNA transcript produced during transcription (except that thymine bases are substituted with uracil bases in the RNA molecule). Though it is not itself transcribed, the coding strand is by convention the strand used when displaying a DNA sequence because of the direct analogy between its sequence and the codons of the RNA product. Contrast template strand; see also sense.
== Structure == LCRs were originally thought to be unstructured and flexible linkers that served to separate the structured (and functional) domains of complex proteins, but they are also capable of forming secondary structures, like helices (more often) and even sheets. They may play a structural role in proteins such as collagens, myosin, keratins, silk, cell wall proteins. Tandem repeats of short oligopeptides that are rich in glycine, proline, serine or threonine are capable of forming flexible structures that bind ligands under certain pH and temperature conditions. Proline is a well-known alpha-helix breaker, however, amino acid repeats composed of proline may form poly-proline helices.
=== Elemental analysis === The ICP-MS allows determination of elements with atomic mass ranges 7 to 250 (Li to U), and sometimes higher. Some masses are prohibited, such as 40 Da, due to the abundance of argon in the sample. Other interference regions may include mass 80 (due to the argon dimer) and mass 56 (due to ArO), the latter of which greatly hinders Fe detection unless the instrument is fitted with a reaction chamber. Such interferences can be reduced by using a high resolution ICP-MS (HR-ICP-MS) which uses two or more slits to constrict the beam and distinguish between nearby peaks. This comes at the cost of sensitivity. For example, distinguishing iron from argon requires a resolving power of about 10,000, which may reduce the iron sensitivity by around 99%. Interfering species can alternatively be distinguished through the use of a collision chamber, which can filter gasses by either chemical reaction or physical collision. A single collector ICP-MS may use a multiplier in pulse counting mode to amplify very low signals, an attenuation grid or a multiplier in analogue mode to detect medium signals, and a Faraday cup/bucket to detect larger signals. A multi-collector ICP-MS may have more than one of any of these, typically Faraday buckets which are more cost-effective than other collectors. With this combination, a dynamic range of 12 orders of magnitude, from 1 part per quadrillion (ppq) to 100 parts per million (ppm) is possible. ICP-MS is a common method for the determination of cadmium in biological samples.
Sources: en.wikipedia.org
== Publications == Marley, Christopher (September 1, 2008). Pheromone: The Insect Artwork of Christopher Marley. Pomegranate Communications. ISBN 978-0764946196. Marley, Christopher (April 14, 2015). Biophilia. Harry N. Abrams. ISBN 978-1419715617. Marley, Christopher (January 1, 2023). Exquisite Creatures: A Dialogue with Art, Nature, and Science. Christopher Marley Studio. ISBN 979-8986360805.
=== Analogues === Analogues of 4-HO-MET include psilocin (4-HO-DMT), 4-HO-DET (ethocin), 4-HO-MiPT (miprocin), 4-HO-DPT (deprocin), 4-HO-MPT (meprocin), 4-HO-DALT (dalocin), and 4-HO-MALT (malocin), among others. 4-AcO-MET (metacetin) and 4-PrO-MET are ester prodrugs of 4-HO-MET. Other analogues of 4-HO-MET include methylethyltryptamine (MET), 5-HO-MET, and 5-MeO-MET.
== Function == The protein encoded by this gene is a noncollagenous extracellular matrix (ECM) protein. It consists of five identical glycoprotein subunits, each with EGF-like and calcium-binding (thrombospondin-like) domains. Oligomerization results from formation of a five-stranded coiled coil and disulfide bonds. Binding to other ECM proteins such as collagen appears to depend on divalent cations. Mutations can cause the osteochondrodysplasias pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED). COMP is a marker of cartilage turnover. It is present in high quantities in fibrotic scars and systemic sclerosis, and it appears to have a role in vascular wall remodeling.
== Further information == Betz Laboratories (1976). Handbook of Industrial Water Conditioning (7th ed.). Betz Laboratories. Ion Exchangers (K. Dorfner, ed.), Walter de Gruyter, Berlin, 1991. C. E. Harland, Ion exchange: Theory and Practice, The Royal Society of Chemistry, Cambridge, 1994. Friedrich G. Helfferich (1962). Ion Exchange. Courier Dover Publications. ISBN 978-0-486-68784-1. {{cite book}}: ISBN / Date incompatibility (help) Kemmer, Frank N. (1979). The NALCO Water Handbook. McGraw-Hill. Ion exchange (D. Muraviev, V. Gorshkov, A. Warshawsky), M. Dekker, New York, 2000. A. A. Zagorodni, Ion Exchange Materials: Properties and Applications, Elsevier, Amsterdam, 2006. SenGupta, Arup K. (2017). Ion exchange in environmental processes: fundamentals, applications and sustainable technology. Hoboken, NJ. ISBN 978-1-119-42125-2. OCLC 1001290476.{{cite book}}: CS1 maint: location missing publisher (link) Dr., I., & Luqman, M. (2012). Ion Exchange Technology I : Theory and Materials. Springer Netherlands. Harland, C. E. (1994). Ion exchange : theory and practice (2nd ed.). The Royal Society of Chemistry.
[PtCl4]2- + 2 H2NCH(R)CO2− → [Pt(H2NCH(R)CO2)2] + 4 Cl− Relevant to bioinorganic chemistry, amino acid complexes can be generated by the hydrolysis of amino acid esters and amides (en = ethylenediamine):
Sources: en.wikipedia.org
Another important property of elements is their electronegativity. Atoms can form covalent bonds to each other by sharing electrons in pairs, creating an overlap of valence orbitals. The degree to which each atom attracts the shared electron pair depends on the atom's electronegativity – the tendency of an atom towards gaining or losing electrons. The more electronegative atom will tend to attract the electron pair more, and the less electronegative (or more electropositive) one will attract it less. In extreme cases, the electron can be thought of as having been passed completely from the more electropositive atom to the more electronegative one, though this is a simplification. The bond then binds two ions, one positive (having given up the electron) and one negative (having accepted it), and is termed an ionic bond. Electronegativity depends on how strongly the nucleus can attract an electron pair, and so it exhibits a similar variation to the other properties already discussed: electronegativity tends to fall going up to down, and rise going left to right. The alkali and alkaline earth metals are among the most electropositive elements, while the chalcogens, halogens, and noble gases are among the most electronegative ones. Electronegativity is generally measured on the Pauling scale, on which the most electronegative reactive atom (fluorine) is given electronegativity 4.0, and the least electronegative atom (caesium) is given electronegativity 0.79.
== History == The band was launched by vocalist Thomas Anselmi and guitarist Christian Thorvaldson, former members of the short-lived and controversial band Slow, with new bassist Eric Marxsen and drummer Pete Bourne. The band was formed in 1987, when Anselmi and Thorvaldson settled on that name after having collaborated under the short-lived band names Mo and Christian Thorvaldson's Freeze-Dried Dog since the demise of Slow. Initially, the band spelled its name as the symbol ©, pronounced as "Circle C". Under that name, they released a self-titled debut album via Geffen Records in 1991. That album sold poorly, and the band was dropped from Geffen. After a few years of struggling to continue in the music industry, they were signed to BMG Music, releasing their second album Love Story in 1996 under the name Copyright. The singles "Transfiguration" and "Radio" were released from that album. Love Story was a shortlisted Juno Award nominee for Best Alternative Album at the Juno Awards of 1998. The album The Hidden World followed in 2001, with the song "Rock Machine" being released as a single. The band disbanded not long after.
== Early life and education == Delibegovic is from Tuzla in Bosnia and Herzegovina. She grew up during the Bosnian War, which forced her family apart. In the early nineties, she moved to Scotland and finished her secondary school education at George Heriot's School in Edinburgh. Delibegovic studied pharmacology at the University of Edinburgh. In the final year of her undergraduate degree Delibegovic moved to Essex, where she did her undergraduate final year project at GlaxoSmithKline on novel anti-diabetes drugs. She completed her doctoral research with Prof Dame Patricia Cohen at the University of Dundee Medical Research Council Protein Phosphorylation Unit. Here she studied the way that enzymes such as protein phosphatase 1 influenced diabetes development. She was supported by the Royal Society studentship. She has said that she was interested in diabetes because of family history and prevalence of Type 2 diabetes in Bosnia and Herzegovina. During her doctoral research, Delibegovic worked closely with pharmaceutical companies to translate her research to the read world. In 2003 she was awarded the American Heart Association personal fellowship to study the role of PTPN1 in glucose homeostasis at the Harvard Medical School in Boston, USA. She spent four years in Boston, working with Prof Benjamin Neel on mouse models of insulin resistance.
==== Parliamentary Commissioner for Standards ==== When the allegations against Galloway emerged in 2003, the UK parliament's Commissioner for Standards began investigating, as Galloway was a Member of Parliament and none of the alleged funding had been declared in the Register of Members' Interests. The Commissioner, Philip Mawer, was overseen by the Standards and Privileges Committee. After a four-year investigation, he published a detailed report in 2007, which concluded:
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.